RITONAVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H48N6O5S2
Molecular Weight	720.9478
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@@]([H])(C(=N[C@@]([H])(Cc1ccccc1)C[C@@]([H])([C@]([H])(Cc2ccccc2)N=C(O)OCc3cncs3)O)O)N=C(N(C)Cc4csc(C(C)C)n4)O

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C37H48N6O5S2
Molecular Weight	720.9478
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020659s065,022417s017lbl.pdf
Curator's Comment:: description was created based on several sources, including: http://www.rxlist.com/norvir-drug.htm https://www.drugs.com/mtm/ritonavir.html http://www.wikidoc.org/index.php/Ritonavir

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 2B6 19 Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159797	Inhibitor 7728	2.2 µM [IC50]
Cytochrome P450 3A 21 Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10952482	Inhibitor 7728	0.14 µM [IC50]
Human immunodeficiency virus type 1 protease 33 Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17627597	Inhibitor 7728	0.01 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 140 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020659s065,022417s017lbl.pdf	Primary		Approved 8043	NORVIR Approved Use KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14) Launch Date 8.2563839E11

C_max

Value	Dose	Co-administered	Analyte	Population
11.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
129 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Disc. AE: Death fetal... AEs leading to discontinuation/dose reduction: Death fetal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 2, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Other AEs: Gastrointestinal disorder NOS, Lipids abnormal... Other AEs: Gastrointestinal disorder NOS Lipids abnormal Insulin resistance Lipoatrophy Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/

AEs

AE	Significance	Dose	Population
Death fetal	1 patient Disc. AE	200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Hypertension	grade 2, 1 patient Disc. AE	50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Gastrointestinal disorder NOS		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Insulin resistance		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipids abnormal		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipoatrophy		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601	inducer 355 inhibitor 1604	inhibitor 1702	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 191 P-gp 1330 CYP2C19 1325 CYP2E1 790 CYP1A2 1383	CYP3A 172 CYP2D 1 CYP3A5 367	CYP3A 118 CYP1A2 637 CYP2C19 269 CYP2B6 501 UGT 27 P-gp 248

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1532	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	no
CYP2E1 871	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	no
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 \| https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: 2.0	yes [IC50 17.3 uM]	yes (co-administration study) Comment: A published trial (Aarnoutse et al 2005) cited previously published data that reported a 145% increase in desipramine with ritonavir 500 mg twice daily dosing. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 \| https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: 2.0
CYP2C19 1392	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	yes [IC50 23.5 uM]
CYP2C9 1648	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	yes [IC50 6.2 uM]
CYP1A2 1532	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
CYP2B6 884	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19.0	yes
CYP2C19 1392	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19.0	yes
CYP2C9 1648	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
CYP3A 271	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
CYP3A 271	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
P-gp 1514	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=51 Page: 51.0	yes
P-gp 1514	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=51 Page: 51.0	yes
UGT 54	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19.0	yes

Drug as victim

Target	Modality	Activity
CYP3A 172	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	major
CYP3A4 1601	substrate 3113 Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: -	yes [Km 0.05 uM]
CYP3A5 367	substrate 3113 Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: -	yes [Km 0.21 uM]
CYP2D 1	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://www.sciencedirect.com/science/article/pii/S0140673605179501 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45409	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45409
ChemicalBook	CB0119429	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0119429
MolPort	MolPort-000-883-877	https://www.molport.com/shop/molecule-link/MolPort-000-883-877
Selleck Chemicals	Ritonavir	http://www.selleckchem.com/products/Ritonavir.html
ZINC	ZINC000003944422	http://zinc15.docking.org/substances/ZINC000003944422
eMolecules	877483	https://www.emolecules.com/cgi-bin/more?vid=877483

PubMed

Title	Date	PubMed
Protease inhibitors shine in triple combinations.	1996 Mar	11363243
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.	1999 Aug	10395861
Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.	1999 Aug 20	10446127
Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient.	1999 Jun 3	10357637
Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir.	1999 May	10452668
Failure of indinavir to inhibit Candida albicans in vitro.	1999 Oct	10584909
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.	2000 Aug	10898681
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.	2000 Dec 15	11141242
In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.	2000 May	10823762
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.	2000 May	10756056
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.	2000 Nov 10	11101056
Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.	2001 Apr	11359661
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.	2001 Apr	11312622
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.	2001 Apr	11259625
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.	2001 Apr	11257038
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.	2001 Apr 13	11371681
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.	2001 Apr 15	11391161
[Overcoming weaknesses in therapy. Protease inhibitors with high IQ].	2001 Apr 2	11373795
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].	2001 Apr 2	11373793
[Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].	2001 Apr 2	11373769
[Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].	2001 Apr 21	11360738
Antiviral drugs: current state of the art.	2001 Aug	11418355
Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.	2001 Feb	11244316
[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].	2001 Feb	11240420
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.	2001 Feb	11236109
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.	2001 Feb	11206045
Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.	2001 Feb	11165122
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.	2001 Feb	11159802
Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.	2001 Feb 10	11177411
Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.	2001 Feb 15	11170979
Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.	2001 Jan	11167671
Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.	2001 Jan 1	11176268
Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.	2001 Jan 1	11176267
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.	2001 Jan 20	11177388
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.	2001 Jan 26	11216928
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.	2001 Jan 26	11216926
The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.	2001 Jan-Feb	11213928
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.	2001 Jul	11423459
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.	2001 Jun	11422025
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.	2001 Jun 1	11343221
The safety and antiviral effect of protease inhibitors in children.	2001 Mar	11253853
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.	2001 Mar	11239054
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.	2001 Mar 1	11242194
Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.	2001 Mar 1	11229864
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.	2001 Mar 30	11317012
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.	2001 Mar 9	11242145
Lopinavir/ritonavir.	2001 Mar-Apr	11296724
Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.	2001 May	11377177
[Effective in HIV: dual combination with indinavir and ritonavir].	2001 May 4	11381644

Patents

Sample Use Guides

In Vivo Use Guide

600 mg twice-day with meals. Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:55:55 UTC 2021` Edited by `admin` on `Fri Jun 25 20:55:55 UTC 2021`
Record UNII	O3J8G9O825
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RITONAVIR

Official Name

English

NORVIR

Brand Name

English

RITONAVIR [VANDF]

Common Name

English

RITONAVIR [MI]

Common Name

English

RITONAVIR [WHO-DD]

Common Name

English

VIRITON

Brand Name

English

EMPETUS

Brand Name

English

RITONAVIR [INN]

Common Name

English

RITONAVIR [USP]

Common Name

English

ABBOTT-84538

Code

English

VIEKIRAX COMPONENT RITONAVIR

Brand Name

English

RITOVIR

Brand Name

English

KALETRA COMPONENT RITONAVIR

Common Name

English

RITONAVIR [HSDB]

Common Name

English

RITONAVIR [USP-RS]

Common Name

English

NSC-693184

Code

English

ABT-538

Code

English

RITONAVIR COMPONENT OF VIEKIRAX

Brand Name

English

RTV

Common Name

English

RITONAVIR [EMA EPAR]

Common Name

English

RITONAVIR [JAN]

Common Name

English

RITONAVIR COMPONENT OF KALETRA

Common Name

English

RITONAVIR [ORANGE BOOK]

Common Name

English

RITONAVIRUM [WHO-IP LATIN]

Common Name

English

A-84538

Code

English

RITOMUNE

Brand Name

English

RITONAVIR RELATED COMPOUNDS MIXTURE

Common Name

English

2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-

Systematic Name

English

RITONAVIR [MART.]

Common Name

English

2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-

Common Name

English

RITONAVIR [USP MONOGRAPH]

Common Name

English

RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]

Common Name

English

RITONAVIR [WHO-IP]

Common Name

English

VIEKIRAX

Brand Name

English

5-THIAZOLYLMETHYL ((.ALPHA.S)-.ALPHA.-((1S,3S)-1-HYDROXY-3-((2S)-2-(3-((2-ISOPROPYL-4-THIAZOLYL)METHYL)-3-METHYLUREIDO)-3-METHYLBUTYRAMIDO)-4-PHENYLBUTYL)PHENETHYL)CARBAMATE

Common Name

English

RITONAVIR [USAN]

Common Name

English

Classification Tree Code System Code

LIVERTOX

853